

Appendix 1 – Countries in Europe

Table 2 . An overview of all European Union member states, the number of centres that are performing PKT surgery and the number of inhabitants <18 years in January 2022.

	Complete response national registry staff member	Number of PKT centers	Pediatric inhabitants
Austria	Yes	3	1 577 640
Belgium	Yes	6	2 368 850
Bulgaria	Yes	0	1 208 260
Croatia	Yes	0	704 718
Cyprus	Yes	1	242 728
Czech Republic	Yes	1	2 019 811
Denmark	Yes	2	1 151 319
Estonia	Yes	1	259 442
Finland	Yes	1	1 042 331
France	Yes	17	13 761 119
Germany	Yes	19	14 180 298
Greece	Yes	2	1 678 096
Hungary	Yes	1	1 677 225
Ireland	Yes	1	441 108
Italy	Yes	6	9 325 877
Latvia	Yes	1	366 926
Lithuania	Yes	2	487 710
Luxembourg	Yes	0	120 754
Malta	Yes	0	76 446
Netherlands	Yes	3	6 849 708
Poland	Yes	1	1 592 785
Portugal	Yes	2	3 552 827
Romania	Yes	3	1 013 774
Slovak Republic	Yes	4	372 542
Slovenia	Yes	1	7 985 493
Spain	Yes	27	2 149 524
Sweden	Yes	4	2 149 524

Appendix 2 – Collected parameters

Table 3. Datapoints collected per registry

	Datapoints	ERK-REG	ESPN/ERA	CERTAIN	Scandia transplant	ERN eUROGEN
Logistic and patients information						
A. Informed consent						
	Patient's permission exists for being contacted for research purposes	Yes	No	Yes	No	Yes
	Patient's consent exists for his/her data to be reused for other research purposes	No	No	No	No	Yes
	Patient's biological sample available for research	No	No	No	No	Yes
	Biological sample type stored in a biobank	No	No	No	No	No
	Other type of biological sample stored in a biobank	No	No	No	No	No
B. Patient Identification						
	Patient ID	Yes	Yes	Yes	Yes	Yes
	First name	No	No	Yes	Yes	No
	Last name	No	No	Yes	No	No
	Patient European Code (SPIDER)	No	No	No	No	Yes
	Patient's pseudonym	No	No	No	Yes	Yes
	Healthcare provider	No	No	No	Yes	Yes
	Patient's date of birth	Yes	Yes	Yes	Yes	Yes
	Patient's sex at birth	Yes	Yes	Yes	No	Yes
	Nationality (Iso code)	No	No	Yes	No	No
	Ethnic Origin	Yes	Yes	Yes	No	No
	Residence country (ISO code)	No	No	Yes	No	No
	Migration background	No	No	Yes	No	No
	Treating Center	Yes	No	Yes	Yes	No
C. Other relevant information						
	Notes about patient's follow-up	No	No	Yes	No	No
	Vaccines after transplantation	No	No	No	No	No
	Has the patient joined a new prospective study since the last visit?	No	No	Yes	No	No
	Name study	No	No	Yes	No	No
	Type	No	No	Yes	No	No
	Study medication	No	No	Yes	No	No
	Blinded study	No	No	Yes	No	No

	Inclusion date	No	No	Yes	No	No
Pre-transplantation parameters						
D. Diagnosis						
D1. Diagnosis General	Age at which symptoms/signs first appeared	Yes	No	No	No	Yes
	Date first presentation to center	Yes	Yes	No	No	Yes
	Renal diagnoses established	Yes	No	No	Yes	Yes
	Date diagnosis established	Yes	No	No	No	Yes
	Select the diagnosis coding ontology					
	Primary renal disease code (PRD)	No	Yes	Yes	Yes	No
	ICD-10 Diagnosis description	No	No	No	No	No
	ORDO Description	No	No	No	No	No
	Describe others ontological classification	Yes	No	Yes	Yes	Yes
	Genetic disease	Yes	No	No	No	No
	D2. Establishing diagnosis	How was diagnosis established?				
Date immunohistochemistry		Yes	No	No	No	No
Conclusion immunohistochemistry		Yes	No	No	No	No
Imaging		Yes	No	No	No	No
Date kidney biopsy		Yes	No	No	No	No
Diagnosis kidney biopsy		Yes	No	Yes	No	No
Immunohistochemical analysis on skin biopsy		Yes	No	No	No	No
Confocal analysis on skin biopsy		Yes	No	No	No	No
Date of genetic screening		Yes	No	No	No	Yes
Was a causative gene abnormality identified?		Yes	No	No	No	Yes
Receipt date of genetic results		Yes	No	No	No	Yes
Methods		Yes	No	No	No	No
Inheritance		Yes	No	No	No	No
Affected gene		Yes	No	No	No	No
Zygosity		Yes	No	No	No	No
Mutation		Yes	No	No	No	No
Other methodologies		Yes	No	No	No	No
E. Pre-transplantation treatment						
E1. Waiting list	Date of inclusion on transplant waiting list	No	No	No	No	No

	Medical Condition	No	No	No	No	No
E2. Status at time of waiting list inclusion	Motor Development:	No	No	No	No	No
	Cognitive Development:	No	No	No	No	No
	Academic Activity Level:	No	No	No	No	No
	Forward to transplant?	No	No	No	No	No
	Renal replacement therapy before transplantation?	Yes	Yes	Yes	Yes	Yes
	Mode of dialysis	Yes	Yes	Yes	No	No
	Months of renal replacement therapy before transplantation	Yes	Yes	No	Yes	No
	Nephrectomy	No	No	Yes	No	Yes
E3. Re-transplantation	Previous transplant?	No	Yes	Yes	No	Yes
	Date of the last previous transplant	No	Yes	No	No	No
	Number of transplants received	No	Yes	Yes	No	Yes
	Date of previous transplant lost	No	Yes	No	No	No
	Cause of previous transplant lost	No	No	No	No	No
	If Others, Cause of previous transplant lost description	No	No	No	No	No
F. Recipients health						
F1. History	History of diabetes	No	Yes	Yes	No	No
	Cardiac event	No	Yes	No	No	No
	CVA	No	Yes	No	No	No
	Vascular event	No	Yes	No	No	No
	Diabetes	No	Yes	No	No	No
	EBV	No	Yes	No	No	No
	History of smoking	No	No	Yes	No	No
	CMV	No	No	No	No	No
	Urological intervention before TX				No	No
F2. Physical examination	Length	Yes	Yes	No	Yes	No
	Weight	Yes	Yes	No	Yes	No
F3. Laboratory findings	Blood group	No	Yes	Yes	No	No
	HLA-A	No	Yes	Yes	No	No
	HLA-B	No	Yes	Yes	No	No
	HLA- DR	No	Yes	Yes	No	No
	Highest PRA	No	Yes	Yes	No	No
	Current PRA	No	No	Yes	No	No
	Creatinine before Tx	No	Yes	No	Yes	No
	eGFR before Tx	No	No	No	Yes	No
	HIV antibody	No	No	No	No	No

	HIV antigen	No	No	No	No	No
	HCV antibody	No	No	No	No	No
	HCV antigen	No	No	No	No	No
	HBc antibody	No	No	No	No	No
	HBc antigen	No	No	No	No	No
F4. Vaccination schedule before transplantation	Vaccines according to age and country schedule?	No	No	No	No	No
	Is the vaccination schedule contraindicated?	No	No	No	No	No
	Accelerated schedule before transplantation?	No	No	No	No	No
	Tetanus	No	No	Yes	No	No
	Diphtheria	No	No	Yes	No	No
	Pertussis	No	No	Yes	No	No
	Poliovirus	No	No	Yes	No	No
	Hep A	No	No	Yes	No	No
	Hep B	No	No	Yes	No	No
	Haemophiles influenzae b	No	No	Yes	No	No
	Pneumococcal	No	No	Yes	No	No
	Meningococcal	No	No	Yes	No	No
	Measles	No	No	Yes	No	No
	Mumps	No	No	Yes	No	No
	Rubella	No	No	Yes	No	No
	Varicella	No	No	Yes	No	No
	Rotavirus	No	No	Yes	No	No
	HPV	No	No	Yes	No	No
	Influenza	No	No	Yes	No	No
	Tick-borne encephalitis	No	No	Yes	No	No
	BCG	No	No	Yes	No	No
	Extended vaccination	No	No	Yes	No	No
	CMV-IgG	No	Yes	Yes	No	No
	EBV-IgG	No	No	Yes	No	No
	Pretreatment viral infections	No	No	Yes	No	No
	Desensitization procedure	No	No	Yes	No	No
G. Donor parameters						
G1. General donor data	Registration date	No	No	No	No	No
	ET donor nr	No	No	No	No	No
	Donor identity	No	No	No	No	No
	Donor age	No	Yes	Yes	No	No
	Gender donor	No	No	Yes	No	No
	Country citizenship	No	No	No	No	No
	Deceased donor type?	No	Yes	Yes	No	Yes

	Date death	No	No	No	No	No
	Cause of death donor	No	No	Yes	No	No
	Date of admission	No	No	No	No	No
	Date of admission ICU	No	No	No	No	No
	Date mechanical ventilation	No	No	No	No	No
	Date urine catheter	No	No	No	No	No
	Cardiac arrest	No	No	No	No	No
	Total duration cardiac arrest	No	No	No	No	No
	Hypotensive period	No	No	No	No	No
	Total duration of hypotensive period	No	No	No	No	No
	Date of last reanimation	No	No	No	No	No
	Duration of last reanimation	No	No	No	No	No
	Number of reanimations	No	No	No	No	No
G2. Physical examination donor	Weight donor	No	No	Yes	No	No
	Length	No	No	No	No	No
G3. History donor	Arterial hypertension donor	No	No	Yes	No	No
	Treatment hypertension	No	No	No	No	No
	Diabetes mellitus	No	No	No	No	No
	Treated	No	No	No	No	No
	Smoking	No	No	No	No	No
	Packyears	No	No	No	No	No
	IV drugs abuse	No	No	No	No	No
	Since	No	No	No	No	No
	Alcohol abuse	No	No	No	No	No
	Since	No	No	No	No	No
	Alcohol consumption	No	No	No	No	No
	Malignancy	No	No	No	No	No
	Malignancy specification	No	No	No	No	No
	Other pre-illness/previous medication	No	No	No	No	No
	PASS score	No	No	No	No	No
	Medication	No	No	No	No	No
	Trade name	No	No	No	No	No
	Dosage	No	No	No	No	No
	Route of administration	No	No	No	No	No
G4. Radiology and pathology donor	Date	No	No	No	No	No
	Type of diagnostics	No	No	No	No	No
	Findings	No	No	No	No	No
	Quality of graft explantation	No	No	Yes	No	No
G5. Laboratory findings donor	Last known renal function donor	No	No	Yes	No	No
	Date	No	No	No	No	No

	Hb	No	No	No	No	No
	Hematocrit	No	No	No	No	No
	Leucocytes	No	No	No	No	No
	Thrombocytes	No	No	No	No	No
	Red blood cell count	No	No	No	No	No
	Blood group donor	No	No	Yes	No	No
	EBV IgG donor	No	Yes	Yes	No	Yes
	CMV IgG donor	No	Yes	Yes	No	Yes
	CMV IgM	No	No	No	No	No
	HLA-A	No	Yes	Yes	No	Yes
	HLA-B	No	Yes	Yes	No	Yes
	HLA-DR	No	Yes	Yes	No	Yes
Transplantation parameters						
H. Transplantation procedure						
	Type of transplant	Yes	Yes	Yes	Yes	Yes
	Combined transplant	No	Yes	No	No	No
	Origin of donor kidney (which center)	No	No	Yes	No	No
	Date of transplantation	Yes	Yes	Yes	Yes	Yes
	Type of graft description	No	No	No	No	No
	Type of Liver graft	No	No	No	No	No
	Type of surgical technique in heart transplantation	No	No	No	No	No
	Type of graft and surgical technique in lung transplantation	No	No	No	No	No
	Type of Intestinal graft	No	No	No	No	No
	Type of pancreas graft/technique description	No	No	No	No	No
	ABO incompatible?	No	No	Yes	No	No
	Relation donor-recipient	No	Yes	Yes	No	No
	Donor/receptor viral sero-mismatch?	No	Yes	Yes	No	Yes
	Type of viral sero-mismatch?	No	No	Yes	No	Yes
I. Surgery						
	Graft left/right	No	No	No	No	No
	Placement	No	No	No	yes	Yes
	Start time incision donor	No	No	No	No	No
	Start time incision recipient	No	No	No	No	No
	Start cold ischemia time	No	No	No	No	No
	End cold ischemia time	No	No	No	No	No
	Cold ischemia time	No	Yes	No	Yes	Yes
	Start reperfusion	No	No	No	No	No

	Kidney on machine	No	No	No	No	No
	Type of machine	No	No	No	No	No
	date and time kidney on machine	No	No	No	No	No
	Total Cold Ischemia Time (if pumped, include pump time): in min	No	No	Yes	Yes	No
	Warm ischemia time	No	No	Yes	No	Yes
	Explanation of previous grafts	No	No	Yes	No	No
	Post-operative drainage	No	No	No	No	Yes
	Ureteral splint after surgery	No	No	No	No	Yes
	Number of days ureteral splint	No	No	No	No	Yes
	TUC after surgery	No	No	No	No	Yes
	Number of days TUC	No	No	No	No	Yes
	SPC after surgery	No	No	No	No	Yes
	Number of days SPC	No	No	No	No	Yes
	Double J catheter after surgery	No	No	No	No	Yes
	Number of days Double J	No	No	No	No	Yes
Post -transplantation parameters						
J. Course of admission						
	Date of discharge	No	No	Yes	Yes	Yes
	On dialysis after transplantation	No	No	Yes	Yes	No
	Date start dialysis	No	No	Yes	No	No
	End of dialysis	No	No	Yes	No	No
	Good function graft at time of discharge	No	No	Yes	Yes	No
	Early Function of the Graft	No	No	Yes	Yes	No
	Any acute rejection episodes between transplant and discharge?	No	No	No	Yes	No
	Type of rejection	No	No	No	Yes	No
	Wound infection	No	No	No	No	No
	Serum creatinine day 0	No	No	No	No	No
	Serum creatinine day 1	No	No	No	No	No
	Serum creatinine day 2	No	No	No	No	No
	Serum creatinine day 3	No	No	No	No	No
	Serum creatinine day 4	No	No	No	No	No
	Serum creatinine day 5	No	No	No	No	No
	Serum creatinine day 6	No	No	No	No	No
	Serum creatinine day 7	No	No	No	No	No

	Number of days in hospitalization after transplant procedure:	No	No	No	Yes	No
K. Status						
K1. Follow up	Follow-up after transplant procedure	Yes	Yes	Yes	Yes	Yes
	Date of other follow-up	Yes	Yes	Yes	Yes	Yes
K2. Patient status	Patient reached adulthood	No	Yes	Yes	No	No
	Describe the cause of lost to follow up	Yes	Yes	Yes	Yes	No
	Patient's date of death	Yes	No	Yes	Yes	Yes
	Primary cause of death	No	Yes	Yes	yes	Yes
	Contributory cause of death	No	No	Yes	No	No
	Last creatinine before death	No	No	Yes	No	No
	Transplant related?	No	No	No	No	No
K3. Graft status/ rejection	Graft status	No	Yes	Yes	Yes	No
	Causes of graft dysfunction or failure:	No	Yes	Yes	No	No
	Renal replacement therapy after graft loss?	Yes	Yes	Yes	Yes	No
	Low compliance cause for graft loss?	No	No	Yes	No	No
	Date of graft rejection/graft loss	No	Yes	Yes	Yes	Yes
L. Nephrological follow-up						
L1. Rejection	Diagnostics	No	No	Yes	No	Yes
	Reason for diagnostics	No	No	Yes	No	No
	Type of rejection (Biopsy proven)	No	Yes	No	Yes	No
	Antibody-mediated changes	No	No	Yes	Yes	No
	Borderline changes	No	No	Yes	Yes	No
	T cell mediated rejection	No	No	Yes	Yes	No
	Interstitial fibrosis and tubular atrophy	No	No	Yes	Yes	No
	Describe pathology findings	No	No	Yes	No	No
	Second biopsy?	No	No	Yes	No	No
	Steroid bolus	No	No	Yes	No	No
	Antilymphocyte antibodies?	No	No	Yes	No	No
	Change in maintenance immunosuppression	No	Yes	Yes	No	No
	Dose increase of maintenance immunosuppression	No	No	Yes	No	No
	Intravenous immunoglobulin H	No	Yes	Yes	No	No
	Blood purification	No	Yes	Yes	No	No

	Outcome after rejection treatment	No	No	No	No	No
	Other(s) causes of dysfunction/failure description:	No	No	No	No	No
L2.1 Physical examination	Physical examination pathological findings	No	No	Yes	Yes	No
	Height (cm)	Yes	Yes	Yes	Yes	No
	Height Z-score <2	No	Yes	No	No	No
	Weight (kg)	Yes	Yes	Yes	Yes	No
	Obesity	No	Yes	No	No	No
	Under nutrition	No	Yes	Yes	No	No
	Bone age in years	No	No	Yes	No	No
	Puberty-Pubic hair	No	No	Yes	No	No
	Puberty-breast	No	No	Yes	No	No
	Puberty- testicular size	No	No	Yes	No	No
	Blood pressure (mmHg)	Yes	Yes	Yes	Yes	No
	Hypertension	No	Yes	Yes	No	No
	Z-score systolic blood pressure	No	Yes	No	No	No
	Z-score diastolic blood pressure	No	Yes	No	No	No
L2.2 Laboratory results	Lab test date	Yes	Yes	Yes	Yes	Yes
	Hemoglobin (g/L)	Yes	No	Yes	No	No
	Serum bicarbonate (mmol/L)	Yes	Yes	Yes	No	No
	Serum inorganic phosphorus (mmol/L)	yes	Yes	Yes	No	No
	Neutrophil count (x10e3/μL)	No	No	Yes	No	No
	Urea	No	Yes	Yes	No	No
	Lymphocyte count (x10e3/μL)	No	No	No	No	No
	Leucocyte count (urine and blood)	No	No	Yes	No	No
	Neutrophil count (urine and blood)	No	No	Yes	No	No
	Platelet count (x10e3/μL)	No	No	Yes	No	No
	Ph Urine and blood	No	No	Yes	No	No
	Total bilirubin (mg/dL)	No	No	No	No	No
	Total bilirubin (mcg/L)	No	No	No	No	No
	AST (UI/L)	No	No	No	No	No
	ALT (UI/L)	No	No	No	No	No
	GGT (UI/L)	No	No	No	No	No
	Albumin (g/dL)	No	Yes	Yes	No	No
	Creatinine (mg/dL)	Yes	Yes	Yes	Yes	No

	Cystatin C (mg/L)	No	No	No	No	No
	eGFR (mL/min/1.73me2)	Yes	Yes	Yes	Yes	Yes
	Ferritin	No	Yes	Yes	No	No
	CRP	No	Yes	Yes	No	No
	Total cholesterol	No	Yes	Yes	No	No
	HDL cholesterol	No	Yes	Yes	No	No
	LDL cholesterol	No	No	Yes	No	No
	Triglycerides	No	Yes	Yes	No	No
	Hypochromic red cells	No	No	Yes	No	No
	Serum iron	No	Yes	Yes	No	No
	Serum transferrin	No	Yes	Yes	No	No
	Sodium (U+B)	No	No	Yes	No	No
	Potassium (u+b)	No	No	Yes	No	No
	Chloride (u+b)	No	No	Yes	No	No
	Calcium	No	Yes	Yes	No	No
	PTH	No	Yes	Yes	No	No
	25-OH-vitamin D	No	No	Yes	No	No
	INR	No	No	Yes	No	No
	Urine Protein	Yes	No	Yes	Yes	No
	Urine albumin	No	No	Yes	Yes	No
	Spot Urine protein-to-creatinine ratio (mg/g)	Yes	No	No	Yes	No
	Spot Urine protein-to-creatinine ratio (mg/mmol)	Yes	No	No	Yes	No
	Spot Urine albumin-to-creatinine ratio (mg/g)	No	No	No	Yes	No
	Spot Urine albumin-to-creatinine ratio (mg/mmol)	No	No	No	Yes	No
	Left ventricular ejection fraction (%)	No	No	No	No	No
	FeV1 (%)	No	No	No	No	No
	FeV1 (L)	No	No	No	No	No
	Fraction exhaled nitric oxide - FeNO (ppb)	No	No	No	No	No
	Immunosuppressive trough level	No	No	Yes	No	No
	Immunosuppressive drug type	No	Yes	Yes	No	No
	Immunosuppressive trough level (ng/mL)	No	No	Yes	No	No
	Immunosuppressive trough level (mcg/mL)	No	No	Yes	No	No
	MMF AUC	No	No	Yes	No	No
	Immunosuppressive drug/metabolite level	No	No	Yes	No	No

	Within the target range trough level?	No	No	Yes	No	No
	Within the target range trough level?	No	No	Yes	No	No
	Within the target range trough level?	No	No	Yes	No	No
	Trough level	No	No	Yes	No	No
	Method	No	No	Yes	No	No
L2.3 Functional status during the follow-up	Motor Development:	No	No	No	No	No
	Cognitive Development:	No	No	No	No	No
	Academic Activity Level:	No	No	No	No	No
L3. Hospitalizations	Required hospitalization?	No	No	Yes	No	No
	Number of hospitalizations since last follow-up	No	No	No	No	No
	Cause of hospitalizations	No	No	Yes	No	No
	Days of Hospitalizations	No	No	Yes	No	No
	Require Intensive care unit?	No	No	No	No	No
	Days in ICU	No	No	No	No	No
L.4 Immunosuppressive treatment	Immunosuppressive treatment (induction and/or initial IS)	No	Yes	No	Yes	Yes
	Days of induction immunosuppression	No	No	No	No	No
	Did patient take immunosuppressive treatment, since last follow-up?	No	No	Yes	Yes	No
	ATG	No	Yes	Yes	No	No
	ALG	No	Yes	Yes	No	No
	OKT3	No	No	Yes	No	No
	Basiliximab	No	Yes	Yes	No	No
	Belatacept	No	No	Yes	No	No
	Daclizumab	No	Yes	Yes	No	No
	Rituximab	No	Yes	Yes	No	No
	Cyclosporin	No	Yes	Yes	Yes	No
	Tacrolimus	No	Yes	Yes	Yes	No
	Tacrolimus delayed release	No	No	Yes	Yes	No
	Sirolimus	No	Yes	Yes	Yes	No
	Everolimus	No	Yes	Yes	Yes	No
	MMF	No	Yes	Yes	Yes	No
	Enteric coated mycophenolate sodium	No	No	Yes	Yes	No
	Azathioprine	No	Yes	Yes	Yes	No
	Prednisone	No	No	Yes	Yes	No
	Prednisolone	No	No	Yes	No	No

	Methylprednisolone	No	Yes	Yes	No	No
	Deflazacort	No	No	Yes	No	No
	Eculizumab	No	Yes	Yes	No	No
L4.1 Per medication	Substance	No	No	Yes	Yes	No
	Trade name	No	No	Yes	No	No
	Status	No	No	Yes	No	No
	Reason	No	No	Yes	No	No
	Date	No	No	Yes	No	No
	route of administration	No	No	Yes	No	No
	Dosing frequency	No	No	Yes	No	No
	Total period dose	No	No	Yes	Yes	No
	Dosing unit	No	No	Yes	Yes	No
L4.2 Toxicity	Toxicity related to immunosuppressive treatment	No	No	No	No	No
	Maintenance	No	No	No	No	No
	Other immunosuppressive treatment description	No	No	No	No	No
	Describe other type of toxicity related to IS	No	No	No	No	No
	Any compliance problem?	No	No	No	No	No
	Toxicity related to Steroids	No	No	No	No	No
	Type of toxicity related to Steroids	No	No	No	No	No
	Mycophenolic acid	No	No	No	No	No
	Toxicity related to Mycophenolic acid	No	No	No	No	No
	Type of toxicity related to Mycophenolic acid	No	No	No	No	No
	Mycophenolate mofetil	No	No	No	No	No
	Toxicity related to Mycophenolate mofetil	No	No	No	No	No
	Type of toxicity related to Mycophenolate mofetil	No	No	No	No	No
	Sirolimus	No	No	No	No	No
	Toxicity related to Sirolimus	No	No	No	No	No
	Type of toxicity related to Sirolimus	No	No	No	No	No
	Everolimus	No	No	No	No	No
	Toxicity related to Everolimus	No	No	No	No	No
	Type of toxicity related to Everolimus	No	No	No	No	No
	Cyclosporine	No	No	No	No	No
	Toxicity related to Cyclosporine	No	No	No	No	No

	Type of toxicity related to Cyclosporine	No	No	No	No	No
	Azathioprine	No	No	No	No	No
	Toxicity related to Azathioprine	No	No	No	No	No
	Type of toxicity related to Azathioprine	No	No	No	No	No
	JAK inhibitors	No	No	No	No	No
	Toxicity related to JAK inhibitors	No	No	No	No	No
	Type of toxicity related to JAK inhibitors	No	No	No	No	No
	Other IS	No	No	No	No	No
	Other immunosuppressive treatment description	No	No	No	No	No
	Toxicity related to Other IS	No	No	No	No	No
	Type of toxicity related to Other IS	No	No	No	No	No
	Describe other type of toxicity	No	No	No	No	No
	Describe toxicity related to immunosuppressive agents	No	No	No	No	No
L.5 Other medication	Did patient take other medications?	No	No	Yes	No	No
	CMV hyperimmunoglobulin	No	No	Yes	No	No
	Trimethoprim and sulfamethoxazole	No	No	Yes	No	No
	Cefaclor	No	No	Yes	No	No
	Trimethoprim	No	No	Yes	No	No
	Nitrofurantoin	No	No	Yes	No	No
	Cefixim	No	No	Yes	No	No
	Ganciclovir	No	No	Yes	No	No
	Valganciclovir	No	No	Yes	No	Yes
	Aciclovir	No	No	Yes	No	Yes
	Valaciclovir	No	No	Yes	No	No
	ACE inhibitor	No	Yes	Yes	Yes	No
	Angiotensine 2 blocker	No	Yes	Yes	Yes	No
	Beta blocking agent	No	Yes	Yes	Yes	No
	Calcium antagonist	No	Yes	Yes	Yes	No
	Diuretic	No	No	Yes	Yes	No
	Recombinant human growth hormone	No	Yes	Yes	No	No
	Darbepoetin alfa	No	No	Yes	No	No
	Epoetin alfa	No	No	Yes	No	No
	Epoetin beta	No	No	Yes	No	No
	Epoetin theta	No	No	Yes	No	No

	Epoetin zeta	No	No	Yes	No	No
	Methoxy-PolyethylenglycolEpoetin beta	No	No	Yes	No	No
	Oral iron supplementation	No	Yes	Yes	No	No
	intravenous iron supplementation	No	Yes	Yes	No	No
	Calcium base phosphate lowering agent	No	Yes	Yes	No	No
	Non-calcium base phosphate lowering agent	No	Yes	Yes	No	No
	1.25OH ₂ VitaminD ₃	No	Yes	Yes	No	No
	1alfa D ₃	No	No	Yes	No	No
	sodium bicarbonate	No	No	Yes	No	No
	sodium citrate	No	No	Yes	No	No
	Detail other medications received	No	No	No	No	No
	Toxicity related to other medications	No	No	No	No	No
	Toxicity related to other medications	No	No	No	No	No
	Describe other type of toxicity related to other medications	No	No	No	No	No
	Use of ESA	No	Yes	No	No	No
M. Oncological follow-up						
M1. General post-transplant malignancy:	Original malignancy relapse	No	No	No	No	No
	Date of relapse	No	No	No	No	No
	Post-Tx de novo malignancy?	No	No	Yes	Yes	No
	Date of post-Tx de novo malignancy diagnosis	No	No	Yes	Yes	No
	Malignancy localization	No	No	Yes	No	No
	Type of malignancy	No	No	Yes	Yes	No
M2. Post-transplant Lymphoproliferative disease (PTLD)	PTLD?	No	Yes	No	Yes	No
	Epstein-Barr Virus associated?	No	No	No	No	No
	PTLD classification (WHO 2017)	No	No	No	No	No
	Date of PTLD diagnosis	No	No	No	No	No
	PTLD localization	No	No	No	No	No
	PTLD Treatment:	No	No	No	No	No
	Other PTLD treatment description	No	No	No	No	No
	Outcome after treatment	No	No	No	No	No
N. Nephrological Complications						

N.1 Infections						
N1.1 CMV infections	Relevant infections episodes	No	Yes	Yes	No	Yes
	Date of infection	No	No	Yes	No	No
	Infection etiology	No	No	No	No	No
	CMV	No	Yes	Yes	No	Yes
	CMV type	No	No	Yes	No	No
	CMV drug resistance	No	No	Yes	No	No
	Kind of mutation	No	No	Yes	No	No
	High dose ganciclovir	No	No	Yes	No	No
	Alternate therapy	No	No	Yes	No	No
	Alternate therapy	No	No	Yes	No	No
	CMV antigenemia (pp65Ag)	No	No	Yes	No	No
	Pos PCR	No	No	Yes	No	No
	Pos. CMV culture	No	No	Yes	No	No
	CMV inclusion bodies	No	No	Yes	No	No
	Histopathological evidence	No	No	Yes	No	No
	Fever > 38 C for last 2 days	No	No	Yes	No	No
	New or increased malaise	No	No	Yes	No	No
	Leukopenia	No	No	Yes	No	No
	>= 5% atypical lymphocytes	No	No	Yes	No	No
	Thrombocytopenia	No	No	Yes	No	No
	Elevation of hepatic transaminases (ALT or AST) to 2 x upper limit of normal (applicable to nonliver transplant recipients)	No	No	Yes	No	No
	Evidence of CMV in blood by viral culture, antigenemia or a DNA/ RNA-based assay	No	No	Yes	No	No
	Other cause of symptoms/ signs identified	No	No	Yes	No	No
	Fever > 38 C for last 2 days	No	No	Yes	No	No
	New or increased malaise	No	No	Yes	No	No
	Leukopenia	No	No	Yes	No	No
	>= 5% atypical lymphocytes	No	No	Yes	No	No
	Thrombocytopenia	No	No	Yes	No	No
	Elevation of hepatic transaminases (ALT or AST) to 2 x upper limit of normal (applicable to nonliver transplant recipients)	No	No	Yes	No	No
	Evidence of CMV in blood by viral culture, antigenemia or a DNA/	No	No	Yes	No	No

	RNA-based assay					
	Other cause of symptoms/ signs identified	No	No	Yes	No	No
	Signs and symptoms of pulmonary disease in the absence of other documented cause	No	No	Yes	No	No
	Evidence of CMV in blood by antigenemia or quantitative PCR	No	No	Yes	No	No
	Bronchoalveolar lavage (BAL) fluid by antigenemia or quantitative PCR	No	No	Yes	No	No
	Detection of CMV in lung tissue by immunohistochemical analysis or in situ hybridization	No	No	Yes	No	No
	Symptoms of upper of lower gastrointestinal disease	No	No	Yes	No	No
	Macroscopic mucosal lesions on endoscopy	No	No	Yes	No	No
	Evidence of CMV in blood or biopsy tissue by antigenemia or quantitative PCR	No	No	Yes	No	No
	Detection of CMV in gastrointestinal tissue by viral culture, immunohistochemical analysis or in situ hybridization	No	No	Yes	No	No
	Elevation of bilirubin and/ or hepatic enzymes in the absence of other documented cause of hepatitis	No	No	Yes	No	No
	Evidence for CMV in blood by antigenemia or quantitative PCR	No	No	Yes	No	No
	Detection of CMV in liver tissue by viral culture, immunohistochemical analysis or in situ hybridization	No	No	Yes	No	No
	CNS symptoms in the absence of other documented cause	No	No	Yes	No	No

	Evidence for CMV in CSF samples by quantitative PCR	No	No	Yes	No	No
	Detection of CMV in CNS tissue by viral culture, immunohistochemical analysis or in situ hybridization	No	No	Yes	No	No
	Retinitis	No	No	Yes	No	No
	Evidence of organ dysfunction in the absence of other documented cause	No	No	Yes	No	No
	Evidence of CMV in blood by antigenemia or quantitative PCR	No	No	Yes	No	No
	Detection of CMV in affected tissue by viral culture, immunohistochemical analysis or in situ hybridization	No	No	Yes	No	No
	General outcome	No	No	Yes	No	No
	Graft function	No	No	Yes	No	No
N1.2 Other infections	EBV	No	Yes	Yes	No	Yes
	BKV	No	No	Yes	No	Yes
	HIV	No	No	Yes	No	No
	HAV	No	No	Yes	No	No
	HBV	No	No	Yes	No	No
	HCV	No	No	Yes	No	No
	HEV	No	No	Yes	No	No
	HSV	No	No	Yes	No	No
	VZV	No	No	Yes	No	No
	Other viral infection	No	No	Yes	No	No
	Pneumocystis jirovecii	No	No	Yes	No	No
	TBC	No	No	No	No	No
	Other fungal	No	No	Yes	No	No
	Bacterial	No	No	Yes	No	No
	Site of infection	No	No	Yes	No	No
	Opportunistic infection	No	No	Yes	No	No
	Catheter related?	No	No	No	No	No
	Amount of UTI in last 12 months	Yes	No	No	No	Yes
	Rectal carrier of resistant bacteria	No	No	No	No	No
N2. Renal	Renal complications	No	Yes	No	No	No

complications	Renal complication treatment	No	No	No	No	No
	Other renal complication treatment description	No	No	No	No	No
	Outcome after treatment of renal complications	No	No	No	No	No
N3. Cardiovascular complications	New onset High blood pressure after transplantation?	No	Yes	Yes	No	No
	Arterial Hypertension treatment	Yes	Yes	Yes	No	No
	systolic blood pressure	No	Yes	Yes	No	No
	diastolic pressure	No	Yes	Yes	No	No
	doppler	No	No	Yes	No	No
	cuff size	No	No	Yes	No	No
	start date	No	No	Yes	No	No
	24 h mean systolic blood pressure	No	No	Yes	No	No
	24 h mean diastolic blood pressure	No	No	Yes	No	No
	24h mean MAD	No	No	Yes	No	No
	24h mean heart rate	No	No	Yes	No	No
	Day period 24 h mean systolic blood pressure	No	No	Yes	No	No
	Day period 24 h mean diastolic blood pressure	No	No	Yes	No	No
	Day period 24h mean MAD	No	No	Yes	No	No
	Day period 24h mean heart rate	No	No	Yes	No	No
	Night period 24 h mean systolic blood pressure	No	No	Yes	No	No
	Night period 24 h mean diastolic blood pressure	No	No	Yes	No	No
	Night period 24h mean MAD	No	No	Yes	No	No
	Night period 24h mean heart rate	No	No	Yes	No	No
	Other arterial hypertension treatment description	Yes	No	Yes	No	No
	Outcome after treatment	No	No	No	No	No
	Transplant-Associated Thrombotic Microangiopathy (TA-TMA)	No	No	No	No	No
	TA-TMA treatment	No	No	No	No	No
	Outcome after treatment	No	No	No	No	No
	Cardiac event	No	No	No	No	No

	CVA	No	No	No	No	No
	Vascular event	No	No	No	No	No
N4. Growth complications	Growth (weight and/or length/height) curves below WHO Z-Score -2?	No	Yes	Yes	No	No
	Type of growth complication	No	No	No	No	No
	When the growth problems began?	No	No	No	No	No
	Reason of growth complications	No	No	No	No	No
	Explain other reason	No	No	No	No	No
N5. Metabolic complications	Metabolic Complications	No	No	No	No	No
	Other metabolic Complications description	No	No	No	No	No
	Diabetes mellitus	No	Yes	Yes	No	No
	Chronic treatment DM	No	No	Yes	No	No
	Insulin dependent DM	No	No	Yes	No	No
	Anorexia	No	No	Yes	No	No
	Hyperparathyroidism	No	Yes	No	No	No
	Cushingoid habitus	No	No	Yes	No	No
	Date metabolic complications	No	No	Yes	No	No
	Outcome metabolic complication	No	No	Yes	No	No
	Type of Bone disease	No	No	Yes	No	No
	Number of fractures	No	No	Yes	No	No
N6. Other complications	Upper gastrointestinal complication	No	No	Yes	No	No
	Lower gastrointestinal complication	No	No	Yes	No	No
	Glaucoma	No	No	Yes	No	No
	Cataract	No	No	Yes	No	No
	Papilledema	No	No	Yes	No	No
	Fundus hypertony	No	No	Yes	No	No
	Gingival hyperplasia	No	No	Yes	No	No
	Hypertrichosis	No	No	Yes	No	No
	Pregnancy	No	No	No	No	No
	Striae	No	No	Yes	No	No
	Skin warts	No	No	Yes	No	No
	Acne	No	No	Yes	No	No
N7. Allergies /autoimmunity	Left ventricular hypertrophy	No	No	Yes	No	No
	De novo allergies following transplant?	No	No	No	No	No
	Date of allergies	No	No	No	No	No
	Describe allergies	No	No	No	No	No

	De novo Autoimmunity/Immune-Mediated disorders following transplant?	No	No	No	No	No
	Date of Autoimmunity/Immune-Mediated disorders	No	No	No	No	No
	Treatment for Autoimmunity/Immune-Mediated disorders	No	No	No	No	No
	Outcome after Autoimmunity/Immune-Mediated disorders treatment	No	No	No	No	No
	Parameter (PRA,HLA 1 antibodies HLA 2 antibodies , Scd30, isoagglutinin)	No	No	Yes	No	No
	Date	No	No	Yes	No	No
	Value	No	No	Yes	No	No
	Unit	No	No	Yes	No	No
	Donor specific antibodies	No	Yes	Yes	No	No
	Assay manufacturer	No	No	Yes	No	No
	Other Autoimmunity/Immune-Mediated disorders description	No	No	No	No	No
N8. Neurological and psychiatric complications	De novo Neurological and/or psychiatric complications following transplant?	No	No	No	No	No
	Date of Neurological and/or psychiatric complications	No	No	No	No	No
	Treatment for Neurological and/or psychiatric complications	No	No	No	No	No
	Other treatment for Neurological and/or psychiatric complications description	No	No	No	No	No
	Outcome after Neurological and/or psychiatric complications treatment	No	No	No	No	No
	Other Neurological and/or psychiatric complications description	No	No	No	No	No
O. Surgical complications and procedures						
	Has the patient had any surgical complications or procedures related to transplantation, since last	No	No	Yes	No	No

	follow up?					
	Which one?	No	No	No	No	No
	Surgical complication type	No	No	No	No	No
	Wound healing problems	No	No	No	No	No
	Vascular	No	No	No	No	No
	Describe the localization of vascular complication	No	No	No	No	No
	Ureteral obstruction	No	No	Yes	No	No
	Urine leakage	No	No	No	No	No
	Renal artery stenosis	No	Yes	Yes	No	No
	Avascular necrosis	No	No	No	No	No
	Thrombosis/embolism	No	Yes	No	No	No
	Specific surgical complications of transplantation	No	No	No	No	No
	Type of venous catheter complication	No	No	No	No	No
	Type of treatment	No	No	No	No	No
	Type of procedure (other than surgical complications treatment)	No	No	Yes	No	No
	Date of surgical complications or procedures	No	No	Yes	No	No
	Outcome after surgical complications or procedures	No	No	Yes	No	No
	If any other has been selected, please describe	No	No	No	No	No
	Procedures after last follow up?	No	No	Yes	No	No
	Describe procedures	No	No	Yes	No	No
	Number of procedures	No	No	No	No	No
	General outcome	No	No	Yes	No	No

CERTAIN: Cooperative European Paediatric Renal TransplAnt Initiative, ERK-Reg: European Rare Kidney Disease Registry, ERN: European Reference Network, ESPN/ERA: European Society of Paediatric Nephrology and European Renal Association

Participating in European registries




Figure 4. Percentage of centers (n=109) that are delivering data to 0,1,2,3 of 4 multinational European registries. No center delivers data to all 5 registries.